Navigation Links
Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
Date:6/24/2008

trials in North America, Europe and Asia, and our accomplished team has been involved in more than 400 clinical trials in the past 14 years. ABR's dedicated staff employ the latest information technology and project management tools coupled with their extensive knowledge and experience to perform, manage, monitor and analyze clinical trials in a cost-efficient and rapid manner.

ABR has evaluated numerous branded and generic compounds in its state-of- the-art Phase I-II clinical research facilities in New Jersey and performs a wide range of clinical trials including first-in-human, dose escalation, bioavailability, bioequivalence, PK/PD, fed-fasted, drug-drug and drug-alcohol interactions, thorough QT (TQT) evaluations, and proof-of-concept studies. Beginning in early 2009, ABR will be among a select few to offer radiolabel studies.

Existing and new clients interested in learning more about the collaborative R&D services of ABR and Frontage may contact Ed Bailey, Director, Business Development at +1 609 818 1800 or e-mail: edward.bailey@abr-clinical.com.


'/>"/>
SOURCE Frontage Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Codexis Appoints Singapore Laboratories Managing Director
2. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
5. Stiefel Laboratories Appoints Two New Members to Board of Directors
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
7. ARUP Laboratories Releases ARUP Consult(R) 2.0
8. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
9. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
10. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
11. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The announced sales of three healthcare ... looking to expand in non-healthcare areas, says Kalorama Information. ... research firm says that  Siemens is the third largest ... of the IVD market , with 5.5 billion in ... composition would likely affect IVD market shares.  ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) http://www.etcbaltimore.com ... today that applications for AccelerateBaltimore™ (AB) 2015 program ... have a big idea?,” asked ETC’s President Deb ... it. AccelerateBaltimore helps you and your big idea ... weeks.” Interested game changers with “big ideas” ...
(Date:11/26/2014)... CA (PRWEB) November 25, 2014 Silicon ... joins forces with RPM Alliance , provider of ... pharmaceutical companies. With the latest addition to its CRO ... free validated EDC system to India. , “We ... a robust and customizable EDC platform which is both ...
(Date:11/26/2014)... 25, 2014 Miles Holder, formerly of ... Graphel Carbon Products team as Sales/Marketing Manager. Mr. Holder ... customer service for the graphite industry. , “We are ... team,” stated Dave Trinkley, VP of Market and Product ... of experience in the graphite industry, along with his ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2
... ADHD symptom control demonstrated from the first time point ... , PHILADELPHIA, June 1 Shire plc ... specialty biopharmaceutical company, today announced that the US Food ... the prescribing information for its once-daily Attention Deficit Hyperactivity ...
... MedImmune Plans to Begin Shipping Seasonal Vaccine to Health ... Md., June 1 MedImmune announced today that the ... awarded the company a contract to manufacture monovalent (single-strain) ... to vaccinate priority populations identified by HHS in the ...
... ALISO VIEJO, Calif., June 1 Valeant Pharmaceuticals International (NYSE: ... Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ... hepatitis C in conjunction with a pegylated interferon. The ... standard design, consisting of 48 weeks of treatment with a ...
Cached Biology Technology:FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1) 2HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1) 3HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1) 4Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 2Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 4
(Date:11/7/2014)... 6, 2014 Leading Biometric companies aim ... security revolutionizing online transactions.  Companies in focus today are: NXT-ID, ... BABA ), Google Inc. (NASDAQ: GOOG ... (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: MA) ... NXTDW), a biometric authentication company focused on the growing mobile ...
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2
... LA JOLLA, Calif., September 12, 2012 The California ... million grant to Huei-Sheng Vincent Chen, Ph.D., associate professor ... one of 28 new projects funded as part of ... research aimed at increasing our understanding of stem cells ...
... in French . , Researchers from Sainte-Justine ... several novel genes that make some children more efficient ... to malaria infection. This world-first in integrative efforts to ... malaria and ultimately to identify the most suitable targets ...
... nuclear fusion reactors has the promise to be safe, sustainable ... fusion energy to the commercial energy market. This is partly ... known. A team of researchers at the University of ... seven other institutions, is trying to change that. Led ...
Cached Biology News:California's stem cell agency boosts heart disease research at Sanford-Burnham 2Genetic make-up of children explains how they fight malaria infection 2University of Tennessee, ORNL lead national team to study nuclear fusion reactors 2University of Tennessee, ORNL lead national team to study nuclear fusion reactors 3
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Lipid Phosphate Phosphohydrolase 2...
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Biology Products: